Teva can keep generic Protonix for now
This article was originally published in The Tan Sheet
Executive Summary
A federal court decision allows Teva Pharmaceutical Industries to continue marketing the generic Rx proton pump inhibitor pantoprazole. The U.S. Court of Appeals for the Federal Circuit affirmed the denial of a motion for a preliminary injunction filed by Wyeth and Altana against the generic equivalent to Wyeth's Protonix delayed-release tablets, the Jerusalem-based firm said May 14. Pantoprazole has received a positive opinion in the European Union for a switch to nonprescription status, and has been mentioned for possible OTC switch in the U.S. (1"The Tan Sheet" Feb. 4, 2008, p. 3). Teva launched generic pantoprazole in December 2007 and said it is still involved in patent litigation with Wyeth and Altana over the product
You may also be interested in...
OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley
Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.